PERICLES登记研究跨大西洋经验:使用烟囱移植物治疗EVAR后Ia型内漏显示良好中期结果
该回顾性分析评估烟囱技术治疗标准EVAR后Ia型内漏的表现。2008年1月至2014年12月,13个美国及欧洲血管中心共完成517例chEVAR,其中39例因持续性Ia型内漏接受治疗并有超过1个月的CTA或MRA随访。技术成功35例(89.7%),30天死亡率2.6%,烟囱移植物36个月一期通畅率94.3%;作者认为chEVAR是治疗Ia型内漏的有效方法。
要点
- 39例EVAR后持续性Ia型内漏患者接受chEVAR,技术成功35例(89.7%)。
- 烟囱移植物36个月一期通畅率为94.3%,30天死亡率为2.6%。
- Endurant与其他支架移植物相比,持续性内漏和再干预无显著差异。
核心结论
- 本系列显示chEVAR治疗EVAR后Ia型内漏的结果令人满意,且不依赖于腹部支架与烟囱移植物的组合。
- 中期结果显示chEVAR是治疗Ia型内漏的有效方法。
研究设计与样本
- 回顾性分析,评估烟囱技术治疗标准EVAR后Ia型内漏的表现。
- 2008年1月至2014年12月,13个美国及欧洲血管中心(PERICLES登记)共完成517例chEVAR。
- 39例患者(平均年龄76.9±7.1岁;33例男性)因持续性Ia型内漏接受治疗,并有超过1个月的CTA或MRA随访。
- 20例使用了Endurant腹部支架移植物。
- 18例(46%)行单烟囱移植物置入,21例(54%)行多烟囱移植物置入;共70条内脏血管目标血运重建。
主要发现
- 技术成功35例(89.7%);最初30天内检出3例持续性Ia型内漏和1例烟囱移植物闭塞。
- 30天死亡率为2.6%。
- 平均随访21.9个月(0.23-71.3)期间发生2例其他死亡(非动脉瘤相关)。
- 烟囱移植物36个月一期通畅率为94.3%。
- Endurant与其他支架移植物比较,持续性内漏[1/20(5%)vs 2/19(11%),p=0.6]和再干预[1/20(5%)vs 0/19(0%)]无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this retrospective analysis was to evaluate the performance of the chimney (ch) technique in the treatment of type Ia endoleaks after standard endovascular aneurysm repair (EVAR). METHODS: Between January 2008 and December 2014, 517 chEVAR procedures were performed in 13 US and European vascular centers (PERICLES registry). Thirty-nine patients (mean age 76.9±7.1 years; 33 men) were treated for persistent type Ia endoleak and had computed tomography angiography or magnetic resonance angiography follow-up at >1 month. Endurant abdominal stent-grafts were used in the 20 cases. Single chimney graft placement was performed in 18 (46%) patients and multiple in 21 (54%). Overall, 70 visceral vessels were targeted for revascularization. RESULTS: Technical success was achieved in 35 (89.7%) cases; 3 persistent type Ia endoleaks and 1 chimney graft occlusion were detected within the first 30 days. Thirty-day mortality was 2.6%. Two other deaths (not aneurysm related) occurred during a mean follow-up of 21.9 months (0.23-71.3). Primary patency of the chimney grafts was 94.3% at 36 months. In a subgroup analysis comparing Endurant to other stent-grafts, no significant differences were observed regarding persistent endoleak [1/20 (5%) vs 2/19 (11%), p=0.6] or reintervention [1/20 (5%) vs 0/19 (0%)]. CONCLUSION: The present series demonstrates that chEVAR in the treatment of post-EVAR type Ia endoleaks has satisfactory results independent of the abdominal and chimney graft combinations. Midterm results show that chEVAR is an effective method for treating type Ia endoleaks.
引用
- Ronchey S, Fazzini S, Scali S, et al. Collected Transatlantic Experience From the PERICLES Registry: Use of Chimney Grafts to Treat Post-EVAR Type Ia Endoleaks Shows Good Midterm Results. J Endovasc Ther. 2018. PMID: 29911481. doi:10.1177/1526602818782941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。